FDA approves AstraZeneca's (AZN.US) Imfinzi for limited-stage small cell lung cancer

The U.S. Food and Drug Administration said Wednesday it approved AstraZeneca's (AZN.US) Imfinzi for the treatment of a subset of adult patients with limited-stage small cell lung cancer, a highly aggressive form of lung cancer that typically recurs and progresses rapidly, even after initial response to chemotherapy and radiation.